Page 40 - Read Online

Chandramohan et al. J Transl Genet Genom 2024;8:394-404 https://dx.doi.org/10.20517/jtgg.2024.38 Page 404

DOI PubMed PMC
9. Baxmann AC, Ahmed MS, Marques NC, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and
serum cystatin C. Clin J Am Soc Nephrol 2008;3:348-54. DOI PubMed PMC
10. Kilbride HS, Stevens PE, Eaglestone G, et al. Accuracy of the MDRD (modification of diet in renal disease) study and CKD-EPI
(CKD epidemiology collaboration) equations for estimation of GFR in the elderly. Am J Kidney Dis 2013;61:57-66. DOI
11. Sakuraba H, Togawa T, Tsukimura T, Kato H. Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme
replacement therapy. Clin Exp Nephrol 2018;22:843-9. DOI PubMed
12. Young E, Mills K, Morris P, et al. Is globotriaosylceramide a useful biomarker in Fabry disease? Acta Paediatr Suppl 2005;94:51-4;
discussion 37. DOI
13. Fogo AB, Bostad L, Svarstad E, et al; all members of the International Study Group of Fabry Nephropathy (ISGFN). Scoring system
for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant
2010;25:2168-77. DOI PubMed PMC
14. Valbuena C, Carvalho E, Bustorff M, et al. Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy.
Virchows Arch 2008;453:329-38. DOI
15. Fischer EG, Moore MJ, Lager DJ. Fabry disease: a morphologic study of 11 cases. Mod Pathol 2006;19:1295-301. DOI PubMed
16. Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for
patients with classic Fabry disease. Mol Genet Metab 2022;137:49-61. DOI
17. van der Tol L, Svarstad E, Ortiz A, et al. Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct
diagnosis. Mol Genet Metab 2015;114:242-7. DOI
18. Najafian B, Silvestroni A, Sokolovskiy A, et al. A novel unbiased method reveals progressive podocyte globotriaosylceramide
accumulation and loss with age in females with Fabry disease. Kidney Int 2022;102:173-82. DOI PubMed PMC
19. Tøndel C, Kanai T, Larsen KK, et al. Foot process effacement is an early marker of nephropathy in young classic Fabry patients
without albuminuria. Nephron 2015;129:16-21. DOI
20. Rusu EE, Zilisteanu DS, Ciobotaru LM, et al. The impact of kidney biopsy for Fabry nephropathy evaluation on patients' management
and long-term outcomes: experience of a single center. Biomedicines 2022;10:1520. DOI PubMed
21. Tøndel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal
albuminuria. Am J Kidney Dis 2008;51:767-76. DOI PubMed
22. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease:
findings from the Fabry registry. Genet Med 2009;11:790-6. DOI PubMed
23. Burlina A, Brand E, Hughes D, et al. An expert consensus on the recommendations for the use of biomarkers in Fabry disease. Mol
Genet Metab 2023;139:107585. DOI
24. Hsu TR, Chang FP, Chu TH, et al. Correlations between endomyocardial biopsies and cardiac manifestations in taiwanese patients
with the Chinese hotspot IVS4+919G>A mutation: data from the Fabry outcome survey. Int J Mol Sci 2017;18:119. DOI
25. Umer M, Kalra DK. Treatment of Fabry disease: established and emerging therapies. Pharmaceuticals 2023;16:320. DOI PubMed
PMC
26. Germain DP, Linhart A. Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry
disease. Front Genet 2024;15:1395287. DOI PubMed PMC